Western Washington University

Western CEDAR
WWU Honors College Senior Projects

WWU Graduate and Undergraduate Scholarship

Spring 2021

Insulin: Roles and Functions in Biochemistry and U.S. Healthcare
Mia Brinkley
Western Washington University

Follow this and additional works at: https://cedar.wwu.edu/wwu_honors
Part of the Cell and Developmental Biology Commons, and the Chemistry Commons

Recommended Citation
Brinkley, Mia, "Insulin: Roles and Functions in Biochemistry and U.S. Healthcare" (2021). WWU Honors
College Senior Projects. 452.
https://cedar.wwu.edu/wwu_honors/452

This Project is brought to you for free and open access by the WWU Graduate and Undergraduate Scholarship at
Western CEDAR. It has been accepted for inclusion in WWU Honors College Senior Projects by an authorized
administrator of Western CEDAR. For more information, please contact westerncedar@wwu.edu.

Mia Brinkley
Insulin: Roles and Functions in Biochemistry and U.S. Healthcare
There is a long list of drugs that treat conditions affecting a large population of the U.S.
today. Genetic predisposition, individual lifestyle, and environmental factors all influence many
of the most prominent diseases in our population, and the development of drugs as a treatment
strategy has brought about both burdens and benefits for the patient. One example of one of these
drugs is insulin, with 30% of Diabetes patients using insulin.1 Today, over 8.3 million people are
prescribed insulin, and that number is expected to grow substantially over time.1 This massive
market is controlled by a small number of manufacturers, causing high cost of insulin and low
accessibility for patients. While a higher percentage of the U.S. population has Type 2 Diabetes
than Type 1, I will be focusing on Type 1 because of its more limited range of treatment options.
Type 1 Diabetes occurs in over 30 million Americans.1 It is caused by an autoimmune
process in which CD8 positive cytotoxic T cells recognize beta-cell autoantigens by recognizing
MHC class I peptide complexes. This produces a chronic inflammatory response to eliminate
insulin-producing beta cells, causing insulin deficiency and hyperglycemia.2 In previous studies,
glutamic acid decarboxylase (GAD) and ICA 512 protein tyrosine phosphatase (in 60-85% of
patients) have been found to
help in elimination of insulin.2
Insulin is naturally
produced by the body, secreted
by pancreatic beta-cell in the
Figure 1. Insulin leaves β-cells of pancreatic Isles of Langerhans
when stimulated. Pipeline includes the pancreas, an Islet of
Langerhans surrounded by acinar cells, and β-cell that is stimulated to
produce and release insulin. Image created using BioRender.

Islets of Langerhans as a 51residue protein.3 This release

is pictured in Figure 1, showing the
release of insulin from pancreatic βcells. The initial protein, proinsulin,
has an A and B chain connected by
disulfide bonds, as shown in the
Figure 2, which is post-translationally
modified to form mature insulin.3
Insulin contains three alpha helices: A1-

Figure 2. Animation of insulin molecule.3

A8, A12-A18, and B9-B19, containing
one intra and two interchain disulfide bonds4 (Figure 3).

Insulin works by binding to the insulin receptor (IR), a homodimer with two alpha
subunits, each at 135 kDa; two beta subunits,
each at 95 kDa; and two minor glycoprotein
(gamma) subunits, each at 210 kDa.5 The
alpha subunit works to bind insulin, and the
beta subunit consists of a tyrosine kinase that
phosphorylates itself at a phosphotyrosine,
phosphoserine, and phosphothreonine (Figure
4). The gamma subunit is the transmembrane
portion, extending through the plasma
membrane to connect to the inside of the cell.
Figure 3. Structure of insulin molecule. Alpha
and beta chains are colored orange and teal,
respectively, with intra and inter-disulfide bonds
labeled with stars.
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Figure 4. A) Overview of tyrosine kinase subunit of insulin receptor protein. Tyrosine kinase is colored
cyan, the swinging loop region is colored magenta, the two Mg2+ coenzymes are colored red, and
multicolored is an ATP analogue, with carbon green, nitrogen blue, oxygen red, and sulfur orange.
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Figure 5. Tyrosine kinase undergoes transitional change upon ATP binding. A) Inactivated tyrosine
kinase region of insulin receptor protein. Highlighted in magenta is part of the loop that swings during
activation, to allow entry into the active site. B) Activated tyrosine kinase, highlighting the loop swing.

plasamembrane to connect to the inside of the cell.

When insulin binds to one of the receptor’s alpha subunit, it causes a shape change that is
propagated into the intracellular region and activates the tyrosine kinases.6 The transition from
the inactive to the active state is shown in Figure 5. The active site binds to ATP, which it uses
to phophorylate its targets. The transition between the inactive and active state is characterized
by several tyrosines being phosphorylated, causing a loop portion to swing out of the active site
and allow ATP and magnesium entry for enzymatic process.6
All of this information that’s known about the insulin protein and insulin receptor is
helpful to researchers to maximize efficiency of Diabetes drugs today, but this information has
not been known nearly as long as Diabetes has been around. Treatments to Type 1 Diabetes,
prior to the use of insulin as a drug, were trying and physically exhausting. Developed in the
early 20th century, starvation therapy was a way to keep sugar below tolerance levels, measured
routinely in urine. This would hopefully prevent organ failure, but it meant that a patient had to
restrict themselves to 800 calories per day.7 This caused weakness and low resistance to
infections, as well as a generally decreased quality of life. Without treatment, diabetes would
start with weight loss, listlessness, hunger, and thirst, as ketones clog organs and the kidneys
begin to fail. Eventually, coma and then death would ensue. Treatments were becoming more
and more important as the 20th century brought cleaner water and better sewage. As child
mortality rates declines, the rates of Type 1 Diabetes increased with the growing population.
Type 2 also increased, as being larger was a sign of wealth and prosperity. A better treatment
was imperative.
However, it wasn’t for lack of trying that the treatment development was slow. Since
1869, when Paul Langerhans identified insulin-secreting pancreatic cells that floated in clusters
of acinar cells—these clusters called islets of Langerhans—there was work on cats, dogs, guinea

pigs, and rabbits to find pancreatic extract for treating patients.7 One group in 1912 thought that
bacterium in milk would cleanse the alimentary canal from excess sugar. Patients were, of
course, told to drink more milk, not knowing of the sugar contained in what they were drinking.
In 1915, J.D. Rockefeller founded a medical research institute, let by Israel Kleiner, to work on
pancreatic extracts. Kleiner’s method was to grind up dog pancreases, put them in solution with
salt, and inject them into the now-diabetic dogs. He found 50% decline in blood sugar levels, but
the negative side effects prevented further investigation.7
The world-changing science was in 1914, when a group of scientists at University of
Toronto banded together to find a way to extract insulin (Figure 6). The team was led by J.J.R.
Macleod and included F.G. Banting, C.H. Best, J.B. Collin, J.Hepburn, J.K. Latchford, and E.
Clark Noble. They used rabbits and developed manufactured pancreatic extract, first calling it
“isletin.” At first
in an oral form—
given to
Banting’s friend
Dr. Joseph
Gilchrist—with
no beneficial
results, it was
Figure 6. Cover of Toronto Daily Star, published on March 22, 1922, showing the
four doctors leading the insulin treatment research.

later successfully

given as an injection to Leonard Thompson, a 14-year old patient of Toronto General Hospital.8
The Toronto group, on January 25, 1922, settled an agreement with Connaught Anti-Toxin
Laboratories for the manufacturing of this extract, but the production failed by March. Collin and

Best succeeded in regaining the formula in May. By May 3rd, the extract was successfully
extracted from cow pancreas and was first referred to as insulin by Macleod. Elizabeth Hughes
Gossett, daughter of U.S. statesman Charles Evans Hughes, was the famous recipient of the first
insulin treatment for Type 1 diabetes, receiving over 42,000 shots from age 12 until her death.7
Banting refused to put the patent for insulin in his name, believing it would be unethical
for a doctor to benefit from the discovery of a life-saving treatment; Collin and Best respected
this decision and agreed to sell the patent for insulin for $1 to the University of Toronto. The
intention was to provide the quickest availability to the public and allow anyone to prepare the
extract with no profitable monopoly to develop.9 While this was meant to prevent monopolizing
on the drug production and distribution, it did little in the end for the benefits of patients. The
University formed the Diabetic Clinic in Toronto General Hospital in June of 1922 and
established the Insulin Committee in August to control licensing, patenting, and trademarking of
the new drug.8 The teamed with Eli Lilly to allow it to take out any U.S. patents “for
manufacturing improvements, but the university would receive the patent right for the rest of the
world, and they let other companies around the world receive the patent from the University.9 By
May of 1923, insulin was made commercially available in Great Britain, and by June, the initial
agreement with Eli Lilly ended, allowing other pharmaceutical companies to apply for licenses
for distribution. By October of 1923, insulin was made commercially available in the U.S. and
Canada. The Nobel Prize in Physiology or Medicine was given to Banting and Macleod that
same month, for their discovery of insulin.10
Over the next three years, production was massive. The world began hearing of the new
drug to treat Diabetes, and what rose was a new hope in patients for a normal way of life. By
1926, insulin was patented or trademarked in 44 countries world-wide. Through the next 100

years, continual work was done to maximize its productivity in the body. At Novo Nordisk, one
the of three companies controlling the insulin market today, Hans Christian Hagedorn added
protamine to the drug to alter its absorption and prolong its duration of action. This was not able
to mix with fast-acting insulin, so he added zinc to the drug and formed neutral protamine
Hagedorn (NPH). This allowed a single daily injection for many patients and was patented in
1946.9 Slow-acting insulins were introduced in the 1950s to extend patents into the 70s, then
introduced monocomponent insulins and single-peak insulins—by Novo Nordisk and Eli Lilly,
respectively—which extended patents into the 80s.
Genentech, a small start-up biotechnology firm with no income and limited resources,
was the first to synthesize and patent human insulin the 1970s.11 They incorporated the gene for
insulin into E. coli—a process called DNA recombination—to harvest the protein from bacterial
fermentation. Human insulin was the first protein to be FDA-approved for treatment using this
method (Figure 7).12 This was only accomplished only a couple years before DNA
recombination and purification was first done and published. With a royalty agreement with Eli
Lilly, human insulin hit the
market as Humulin R in 19829
and instigated a surge in
investment in biotechnology. And
it worked better for patients.
Only six years later,
Nordisk brought its first human
insulin to market, using
Figure 7. Illustration of the recombination process to produce
isolated human insulin.12

biochemical methods to convert

bovine insulin to human insulin.9 Not long after, Sanofi did the same, and human insulin would
determine the three companies to own the entire insulin market for the following forty years.
Today, insulin treatment is much more than a single-type injection that is the same for
every patient. In 1977, human insulin was synthetically manufactured from recombinant DNA
and replaced beef and pork insulin.13 Today, insulin analogs are replacing human insulin because
they are less likely to clump together in high concentrations under the skin, causing slow and
unpredictable absorption from subcutaneous tissue the way human insulin does. Analogs have a
more predictable duration of action, and work quicker, last longer, and have a less peak-like
effect. As of 2010, only 15% of the insulin market uses human insulin, while 92% use analog
insulin.14
There are three types of insulin. Fast-acting insulin, as the name suggests, is absorbed
quickly from subcutaneous tissue into the bloodstream and is used during meals to regulate blood
sugar levels.13 These include rapid-acting insulin analogs—such as Insulin Aspart, Lyspro, and
Glulisine—with an onset time of 5-15 minutes, a peak effect of 1-2 hours, and an overall
duration of 4-6 hours. There is also regular human insulin, with an onset time of 30 minutes-1
hour, a peak effect of 2-4 hours, and a duration of 6-8 hours. Another type is intermediate-acting
insulin, which absorbs slower and lasts longer. This is used overnight, while fasting, and between
meals. It includes NPH human insulin, with an onset of 1-2 hours, a peak effect of 4-6 hours, and
a duration over 12 hours; and premixed insulin, a mixture of NPH and regular human insulin of
rapid-acting analog. This gives a combination of short and intermediate-acting insulins. The third
type is long-acting insulin, which is absorbed slowly, has minimal peak effect, and a stable
plateau over most of the day. This is used overnight, while fasting, and between meals, and it
mainly consists of long-acting insulin analogs—such as Insulin Glargine and Detemir—with an

onset of 1.5-2 hours, when the effect plateaus then holds a flat duration of action of 12-24
hours.13 Figure 8 visualizes these effects.
Most patients with Type 1 Diabetes must take basal insulin throughout the day, which
controls insulin levels between meals, as well as mealtime insulin to control those levels during
meals, when glucose intake spikes.14
A typical day consists of one or two
injections of long-acting, and rapidacting for every meal. Type 2
patients may only need long-acting
insulin injections. Most patients still
use syringes as the delivery method.
While insulin pens combine the vial
and syringe, being safer and more

Figure 8. Activity profiles of different types of insulin on the
market today.13

convenient, they are used less because of higher cost. CSII devices—Continuous subcutaneous
insulin infusion devices—are battery-powered, computerized, and deliver short-acting insulin
under the skin continuously throughout the day via an abdominal catheter. These are also
expensive but can last years and are commonly used. Another delivery method is infusion, using
a direct IV, but this is reserved for patients when in a hospital. A new method is inhaled insulin,
which is rapid-acting and meant to be used before meals, in combination with long-acting
insulin.
There are other medications to treat insulin today that are not insulin, called oral
antidiabetic drugs (OADs). One is Metformin, a treatment for Type 2 Diabetes that most
commonly works in conjunction with insulin. It has been used since the 1950s, only briefly taken

off the market due to concerns of lactic acidosis, and acts by blocking a mitochondrial redox
shuttle to inhibit gluconeogenesis in the liver.15 Another class of drugs are glucagon-like peptide
1 (GLP-1) receptors, which also work in Type 2 Diabetes patients to increase insulin secretion in
response to oral and intravenous glucose.16 Another common medication includes sodium
glucose co-transporter 2 (SGLT-2) inhibitors. These work in combination with insulin for Type 1
and Type 2 Diabetes. SGLT-2 inhibitors block the reabsorption of glucose by the kidney and
reducing blood glucose levels as glucose is excreted from the body.17 While these classes of
drugs provide promising progress toward helping those with Diabetes, they are commonly only
given to Type 2 patients and almost always still work in conjunction with insulin. Making OADs
more accessible to Type 2 users is a worthwhile endeavor, but the significant problem still
remains of providing all DM affordable access to the still most-widely used medications, insulin.
Over 8.3 million people in the U.S. require insulin. And the worldwide market is
expected to increase by at least 20% by 2030.14 To begin with the problems of the insulin
market, there is limited competition for three major reasons. Insulin products are not
interchangeable, there are currently only three insulin manufacturers in the U.S. market, and
there have been no regulations to allow biosimilar products to form a generic insulin.
The cost of insulin today is outrageous. From 2002 to 2016, the price of insulin has
increased by 218%.18 The last four years of that period, the increase was 450% above general
inflation. Estimated cost of spending, per patient, has increased from $231.48 in 2002 to $736.09
in 2013.19 And the average price of insulin has increased from $4.34 to $12.92 per milliliter from
2002 to 2013. These are partially due to continually newer and “better” insulin products coming
to market, raising the cost and patents, but these increasing costs are discouraging patients from

wanting to switch to newer insulin when they do work better. Many patients are afraid of not
being able to pay their medical bills or of losing their health insurance altogether.
While the high cost of insulin is not new or that surprising, it affects millions of
Americans each year. In a 2019 Yale study, 25.5% of insulin users reported cost-related insulin
underuse.20 This is both dangerous and unacceptable, and highlights “an urgent need to address
affordability of insulin.”
Because of non-interchangeable insulin products, there is little competition in the insulin
market. There are large differences in insulin types, so patients cannot easily change them.14
With this, there is little autonomy in patient decisions on what form of insulin is best for them,
and changing forms is left for the provider to decide.
The three insulin manufacturers are Eli Lilly, Novo Nordisk, and Sanofi, representing
over 90% of the global insulin market.14 While each of these companies have multiple types,
Novo Nordisk have a monopoly on ultra-long acting insulin. This is because of patents. Patents
last 20 years, and companies can receive a new patent every time they improve the way to
produce or administer the drug, or with changes in duration or onset time. For insulin
specifically, this can be for using new, non-active ingredients, changing the manufacturing
processes, or developments in administration devices. Patents have followed the development of
insulin through time, starting with animal insulin in 1923, the first human insulin in 1982, and
new analog patents from 1996-2005.14 When a new product comes to market, older products are
less prescribed and often discontinued from the manufacturer. This prevents patients from having
access to off-patent insulins, which would potentially be cheaper. If one looks at the minor
changes in insulin from 1996 to 2005, the price increase of the newly-patented insulin is often
not balanced by equally-improved effects. For example, analogue insulin has shown improved

effects compared to human insulin, as discussed earlier, but the estimated expenditure per patient
in 2013 was $228.20 for human insulin and $507.89 for analog, making it significantly less
affordable.19
To complicate things, insulin has been considered a drug rather than a biological drug or
biologic. This designation does not allow generic versions to be made when the patent expires.
As of 2009, however, the FDA created a legal path for biosimilars to reach the market, called the
Biologics Price Competition and Innovation Act.21 This changed the designation from a drug to a
biological product. Other companies can now create biosimilar product—where they would
previously be called generics—where the molecular and biological structure doesn’t show any
clinically meaningful difference from the biologic. This provision took effect on March 23, 2020,
and is predicted to lower the cost of insulin as other companies produce these biosimilars.
This transition of insulin’s designation should not be discounted. Generics are an
enormous market in the drug industry. Over 80% of prescriptions are for generic drugs; this
saves health care systems billions of dollars each year and are critical for payers and patients.9
And yet, there is some skepticism in the savior mentality of producing generics to fix the insulin
price. With this Act, insulin companies are still allowed the usual patents of 20 years when they
introduce “improvements,” and with such a large molecule, there is a large number of possible
incremental changes. This is the process has been continuing since insulin first came to market
and is referred to as “evergreening.” Developing a biosimilar is incredibly challenging, as
biologics are huge molecules compared to drugs. Creating biosimilars take about twenty-two
times the cost of creating a small-chemical molecule drug, and this expense will slow
competitors and possibly prevent any price drops.14 It is incredibly difficult to prove that two
molecules are structurally identical, which is necessary for a generic. There is also a more

extensive approval process that will slow progress and add expenses. This is the case in Europe:
recently, they have introduced generic insulin, but the price reductions were 20-40% instead of
the usual 80% for introduction of a generic.9

Figure 9. Pharmaceutical supply chain of medicine distribution.1

A study done by The Commonwealth Fund suggests a different tactic in increasing
affordability: Increase both the access to insurance coverage and the generosity of that coverage
for insulin patients.1 Reporting that as many as ¼ of insulin patients report rationing insulin to
save money, policies need to be implemented to expand Medicaid and limit out-of-pocket
spending for those with private insurance. Commonwealth goes into detail about the complicated
process of insulin reaching the user, shown in Figure 9. Manufacturers give rebates to PBMs, or

Pharmacy Benefit Managers, and collect the entire net price of insulin minus those rebates, fees
paid to wholesalers, and discounts paid to pharmacies. Each of these payments are kept at a
specific percentage of the overall list price, giving the manufacturers incentive to keep the price
high, benefiting everyone but the user.
Ultimately, whether reducing list prices, limiting deductibles, expanding Medicaid, or
improving health insurance is the solution depends on whether the user has insurance or not.
While those with Medicaid pay nothing out of pocket, uninsured users pay list prices, unless
they’re part of manufacturer programs or free clinics, which are rare. Thus, expanding Medicaid
could be an option to help many low-income users, who often try to use older insulin
formulations because of lower prices, which are associated with higher risks of hypoglycemic
episodes, nocturnal hypoglycemia, and increased within-subject variability of blood glucose.1
For uninsured prescriptions (those without Medicaid), 47% were paid 100% out of pocket and
only 21% had 0% out-of-pocket cost. Additionally, 71% of uninsured prescriptions were more
than $100 out of pocket.1 Patients are often uninsured because of low socioeconomic status, and
these high prescription costs add significant financial stress.
Those with are privately insured and under 65 pay varying out-of-pocket costs, consisting
of copayments or an insurer-established price, up to a deductible, plus a coinsurance amount up
to an out-of-pocket max. Lowering these deductibles and maximums is another strategy, and
progress has been made here: In Washington State, the Senate bill 6087 issued a state-wide cap
of $100 per month that began on January 1, 2021.22 This cap has been introduced to several
western states in the last three years.
The Affordable Care Act (ACA), enacted in 2010 under the Obama administration,
required all states to expand Medicaid eligibility to adults with incomes below 138% of the

federal poverty level.23 The US Supreme Court ruled that expansion could be voluntary for each
state. In 2014, twenty-nine states expanded Medicaid eligibility, and the effects were observed.
Many were general improvements, such as easier access to primary care, increased health care
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Figure 10. Percent increase in Diabetes medications over expanded Medicaid eligibility. Changes
recorded as averages over 2014 and 2015, as 29 states expanded in both years. Other non-insulin
Medications include DPP-4 inhibitors, GLP-1 agonists, and SGLT-2 inhibitors.

use, and increase in the number of Medicaid prescriptions. A study done by Myerson, et al.
aimed to measure the change in different types of Medicaid diabetes prescriptions when the
eligibility expanded, hoping to see whether the expansion helped lower-income patients with
diabetes progress to using the newer and better medications.23 As shown in Figure 10, the
change in Diabetes medications showed significant increase over the period of eligibility

expansion from 2014 to 2015. Insulin, insulin analogues constituted about a third of the increase
at 9%, indicating easier access. The last four columns track newer medications and show that as
much as a third of the increase was likely to newer medications for patients who previously
lacked insurance and could not pay the high out-of-pocket costs.23 Additionally, the increase in
prescription fills was significantly higher as patients reached sixty-five, following the trend of
Diabetes prevalence increasing with age. The exception was an 82% lower increase for people
65-69 than for people ages 60-64, which was expected, as the older age group is also eligible for
Medicare, which will be used first. Overall, the study revealed an average of thirty new Medicaid
prescriptions per 1,000 people in states that expanded eligibility.23 Prescriptions for insulin types
cumulatively reached nearly a 40% increase after expansions, revealing the greater access when
the expensive full costs of insulin are covered by Medicaid. Myerson asserts that “gaining
Medicaid insurance would have significantly reduced out-of-pocket spending for insulin for
previously uninsured patients, thereby facilitating uptake of the medication.” Expanding
Medicaid not only saved people money or encouraged use of insulin, but encouraged use of
newer insulin for lower-income patients.
Thus, there are several ways to increase insulin accessibility. Allowing generic
production, regulation of list prices and deductibles for those with insurance, and especially
expanding Medicaid for those without insurance are all promising ways to cumulatively increase
access and affordability of insulin and insulin analogues. The focus needs to be on accessibility
on the newer insulin treatments for those with lower incomes. As insulin remains to be
imperative for treatment of Diabetes for all patients, we need to address insulin accessibility in
policy initiatives to work toward expansion.
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